Compare EVEX & ANL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EVEX | ANL |
|---|---|---|
| Founded | 2020 | 2004 |
| Country | United States | United States |
| Employees | 198 | N/A |
| Industry | Aerospace | |
| Sector | Industrials | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 895.1M | 731.6M |
| IPO Year | N/A | 2022 |
| Metric | EVEX | ANL |
|---|---|---|
| Price | $2.84 | $10.00 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 1 |
| Target Price | $6.88 | ★ $20.00 |
| AVG Volume (30 Days) | ★ 956.4K | 98.0K |
| Earning Date | 05-05-2026 | 04-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $36.02 |
| Revenue Next Year | $11,676.47 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.34 | $0.88 |
| 52 Week High | $7.70 | $17.25 |
| Indicator | EVEX | ANL |
|---|---|---|
| Relative Strength Index (RSI) | 46.00 | 41.90 |
| Support Level | $2.81 | $9.46 |
| Resistance Level | $3.18 | $12.59 |
| Average True Range (ATR) | 0.19 | 1.12 |
| MACD | -0.03 | -0.03 |
| Stochastic Oscillator | 31.68 | 17.66 |
Eve Holding Inc is a provider of Urban Air Mobility solutions. The company's operating segments are; eVTOL that includes; the design and production of electric vertical take-off and landing vehicles (eVTOLs) including fixed wing and helicopter operators, as well as lessors that purchase and manage aircraft on behalf of operators; Service and Operations Solutions segment which includes a portfolio of maintenance and support services focused on its and third-party eVTOLs; and the UATM segment, a new Urban Air Traffic Management system designed to allow eVTOLs to operate safely and efficiently in dense urban airspace alongside conventional aircraft and drones.
Adlai Nortye Ltd is a clinical-stage company at the forefront of discovering and developing cancer therapies. The company is building a robust pipeline of drug candidates focused on two key areas where it believes it can make a difference RAS-targeting therapies: its is tackling RAS-driven cancers with AN9025, an oral pan-RAS(ON) inhibitor, and AN4035, a CEACAM5-targeting ADC delivering a potent pan-RAS(ON) inhibitor directly to tumors; Next-generation cancer immunotherapies: its candidates, AN8025 (a tri-functional fusion protein of alphaPD-L1 x CD86 variant x LAG3 variant), a T-cell and antigen-presenting cell modulator, and AN4005 (a first-in-class oral small-molecule PD-L1 inhibitor), are designed to activate cancer immunity in novel ways.